The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02537925|
Recruitment Status : Unknown
Verified August 2015 by Changjie Huang, Nanning Second People's Hospital.
Recruitment status was: Recruiting
First Posted : September 2, 2015
Last Update Posted : September 2, 2015
Information provided by (Responsible Party):
Changjie Huang, Nanning Second People's Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2016|
Soo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, Tan KB, Low JS, Lai YF, Mow B, Hsu S, Loh KS, Tan L, Tan P, Goh BC. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol. 2006 Nov;17(11):1625-30. Epub 2006 Sep 28. Erratum in: Ann Oncol. 2007 Mar;18(3):611. Soon, W L [corrected to Low, J S W].
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: a phase II-III clinical trial. J Cancer Res Ther. 2011 Oct-Dec;7(4):442-7. doi: 10.4103/0973-1482.92013.